Mavenclad may help manage coexisting autoimmune diseases alongside MS, potentially reducing the need for extra drugs.

Mavenclad (cladribine) is a brand-name oral tablet that’s prescribed for certain types of multiple sclerosis (MS) in adults. The cost of the drug, with and without insurance, can depend on several ...

If you have a certain kind of multiple sclerosis (MS), your doctor may recommend treatment with Mavenclad. Mavenclad is a prescription drug used to treat relapsing types of MS in adults. To learn more ...

Mavenclad (cladribine) is a prescription drug used to treat relapsing forms of multiple sclerosis (MS). Mavenclad can cause side effects that range from mild to serious. Examples include: headache and ...

Accelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in healthcare sales in the third quarter, and a rise in its full-year revenue ...

Mavenclad (cladribine) is a medicine used to treat relapsing forms of multiple sclerosis (MS) including relapsing-remitting MS and active secondary progressive MS. Relapsing forms of MS have temporary ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.

In an increasingly crowded multiple sclerosis market, Merck KGaA's Mavenclad has scrapped for market share against behemoths such as Roche's Ocrevus. But a year into its U.S. launch, Mavenclad is ...

DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Mavenclad" drug pipelines has been added to ResearchAndMarkets.com's offering. Mavenclad contains cladribine, a small molecule that suppresses the immune ...

"Having a new MS treatment approved in Argentina is very motivating," said Dr. Jorge Correale M.D., the Head of Neuroimmunology and Demyelinating Diseases at the Institute for Neurological Research Dr ...

(HealthDay)—Mavenclad (cladribine) tablets were approved to treat adult patients with relapsing-remitting and active secondary progressive multiple sclerosis (MS) who have inadequately responded to or ...